LU45106A1 - - Google Patents

Info

Publication number
LU45106A1
LU45106A1 LU45106DA LU45106A1 LU 45106 A1 LU45106 A1 LU 45106A1 LU 45106D A LU45106D A LU 45106DA LU 45106 A1 LU45106 A1 LU 45106A1
Authority
LU
Luxembourg
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU45106A1 publication Critical patent/LU45106A1/xx

Links

LU45106D 1962-12-27 1963-12-23 LU45106A1 (https=)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5790262 1962-12-27
JP6427663 1963-10-29
JP5741963 1963-10-29
JP6250163 1963-11-22

Publications (1)

Publication Number Publication Date
LU45106A1 true LU45106A1 (https=) 1964-02-24

Family

ID=27463499

Family Applications (1)

Application Number Title Priority Date Filing Date
LU45106D LU45106A1 (https=) 1962-12-27 1963-12-23

Country Status (5)

Country Link
BE (1) BE641880A (https=)
FR (1) FR3150M (https=)
GB (1) GB1080599A (https=)
LU (1) LU45106A1 (https=)
NL (1) NL302572A (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2495608A1 (fr) * 1980-12-04 1982-06-11 Morelle Jean Nouveaux derives de l'acide aspartique et leurs usages
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
CN107540413A (zh) * 2017-09-14 2018-01-05 精晶药业股份有限公司 一种从门冬氨酸鸟氨酸结晶母液中提取尿素的方法

Also Published As

Publication number Publication date
GB1080599A (en) 1967-08-23
FR3150M (fr) 1965-02-22
NL302572A (https=)
BE641880A (https=) 1964-04-16

Similar Documents

Publication Publication Date Title
BE616548R (https=)
BE621553A (https=)
BE632887A (https=)
BE380301A (https=)
BE489310A (https=)
BE538252A (https=)
BE538831A (https=)
BE541929A (https=)
BE553896A (https=)
BE559145A (https=)
BE586180A (https=)
BE592434A (https=)
BE599783A (https=)
BE604335A (https=)
BE608197A (https=)
BE609543A (https=)
BE612190A (https=)
BE612311A (https=)
BE612464A (https=)
BE612847A (https=)
BE612926A (https=)
BE613108A (https=)
BE613190A (https=)
BE613298A (https=)
BE613319A (https=)